Analysts Anticipate Sanofi (SNY) Will Post Quarterly Sales of $10.91 Billion
Wall Street analysts expect Sanofi (NYSE:SNY) to announce sales of $10.91 billion for the current quarter, according to Zacks. Three analysts have made estimates for Sanofi’s earnings. The highest sales estimate is $11.13 billion and the lowest is $10.52 billion. Sanofi reported sales of $10.07 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.3%. The business is expected to announce its next quarterly earnings report before the market opens on Thursday, November 2nd.
On average, analysts expect that Sanofi will report full-year sales of $10.91 billion for the current fiscal year, with estimates ranging from $40.90 billion to $42.22 billion. For the next fiscal year, analysts forecast that the company will report sales of $42.80 billion per share, with estimates ranging from $42.57 billion to $43.38 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Sanofi.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. The business’s revenue for the quarter was down 2.3% on a year-over-year basis.
A number of equities analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. HSBC Holdings plc upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Argus restated a “buy” rating and set a $55.00 target price on shares of Sanofi in a report on Friday, September 1st. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Finally, BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. Sanofi currently has a consensus rating of “Hold” and an average target price of $53.50.
Shares of Sanofi (SNY) opened at 49.01 on Wednesday. The company has a market capitalization of $123.09 billion, a P/E ratio of 11.38 and a beta of 0.87. Sanofi has a 12-month low of $36.81 and a 12-month high of $50.65. The company’s 50 day moving average is $49.53 and its 200 day moving average is $48.41.
In other Sanofi news, major shareholder Sanofi bought 60,595 shares of Sanofi stock in a transaction dated Wednesday, August 23rd. The stock was bought at an average price of $478.98 per share, with a total value of $29,023,793.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.00% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Pennsylvania Trust Co boosted its position in shares of Sanofi by 0.4% in the second quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock valued at $402,000 after acquiring an additional 37 shares during the period. Moors & Cabot Inc. lifted its position in Sanofi by 0.7% during the second quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock worth $311,000 after purchasing an additional 43 shares during the period. Rehmann Capital Advisory Group lifted its position in Sanofi by 0.7% during the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock worth $347,000 after purchasing an additional 47 shares during the period. Strategic Global Advisors LLC lifted its position in Sanofi by 0.6% during the second quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock worth $414,000 after purchasing an additional 54 shares during the period. Finally, First City Capital Management Inc. lifted its position in Sanofi by 0.3% during the second quarter. First City Capital Management Inc. now owns 38,389 shares of the company’s stock worth $1,839,000 after purchasing an additional 100 shares during the period. 9.35% of the stock is owned by institutional investors.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.